MedTrace Logo

Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis

NCT05001984 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-26

No results posted yet for this study

Summary

This study will evaluate whether low-density lipoprotein (LDL-C) lowering with alirocumab results in greater change from baseline in intracranial atherosclerotic plaque at week 26 than control in adults with acute ischemic stroke from intracranial atherosclerosis taking lipid lowering therapy.

Conditions

  • Intracranial Atherosclerosis
  • Acute Ischemic Stroke
  • ICAS - Intracranial Atherosclerosis

Interventions

DRUG

Alirocumab

Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.

Sponsors & Collaborators

  • Chang Gung University

    collaborator OTHER

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Yenchu Huang, MD · Chang Gung Memorial Hospital, Chiayi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2025-04-15
Completion
2025-04-15
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001984 on ClinicalTrials.gov